Genomic Biomarker Market Size To Rise USD 8.6 Billion By 2030

---

Table of Content

The global genomic biomarker market size surpassed USD 4.84 billion in 2022 and is projected to rise to USD 8.6 billion by 2030, anticipated to grow at a strong CAGR of 7.46 percent during the projection period from 2022 to 2030.

Market Overview:

Biomarkers indicate the pathogenic process; it has multiple uses in cancer diagnoses, such as prognosis, therapeutics response, risk assessment, and monitoring of disease progression. The rising prevalence of cancer in the population will likely boost the demand for genomics biomarkers. The growth of the global genomic biomarker market is supported by the growing cases of chronic diseases and the increasing need for personalized medicine across the globe. The enhanced focus on research and development activities will boost the growth of the market in the upcoming period.

Biomarkers can specifically be used for the identification of ovarian and gastric cancer. The increasing number of ovarian and gastric cancer cases and the continuous laboratory and clinical technological advancements in the analyzed period fuel the development of the genomics biomarker market.

Regional Snapshot:

North America dominated the global genomic biomarkers market with the most significant market share revenue in 2022. The region will continue its dominance due to the rising prevalence of chronic diseases due to the changing lifestyle and eating habits in the area. The increasing technological advancements in the pharmaceutical industry resulted in the growth of the genomics biomarker market. Rising research and development programs for the development of the genomic biomarker market in countries like the United States, Canada, etc., are anticipated to propel the growth of the genomic biomarker market.

Asia Pacific is expected to witness the fastest growth in the global genomic biomarkers market during the forecast period. China, Japan, South Korea, and India are expected to be the largest and most significant contributors to the growth of the market in the region. The considerable investments in the development of the pharmaceutical industry by both private and government institutions promote the growth of the market in the Asia Pacific. The rising emphasis on various genetic testing activities and research associated with the improvement of the healthcare industry is expected to fuel the market’s growth in the Asia Pacific.

Genomic Biomarker Market Report Scope:

Report Highlights:

• By Type, the segment is further divided into predictive biomarkers and prognostic biomarkers. In which the prognostic biomarker segment dominated the market with the largest market share in 2022, the segment is expected to grow at a notable rate during the forecast period. The growth of the segment is attributed due to the rising demand for genetic testing services, primarily to diagnose cancer patients.
• By disease Indication, the segment is further divided into neurological disorders, oncology, renal disorders, cardiovascular disorders, and others. The cardiovascular diseases segment is expected to dominate the market with the largest market share in the forecast period. Genomic biomarkers directly increase access to high-quality and dependable health interpretations while diagnosing patients with cardiac diseases.
• By end-user, the segment is divided into diagnostic centers, hospitals, and others. The hospital segment is anticipated to witness the highest growth rate in the analyzed period. The segment's growth is attributed to the maximum use of biomarkers with the rapid and accurate diagnosis of various diseases by healthcare providers. Hospitals' rapid adoption of advanced healthcare services also promotes the segment’s growth.

Market Dynamics:

Drivers:

Increasing prevalence of cancer across the globe

The increasing prevalence of several types of cancer, such as breast cancer, ovarian cancer, prostate and lung cancer, etc., is likely to be higher in the market demand for genomics biomarkers. Biomarkers are used to target disease and organ segments of human health. Biomarkers are specifically gaining popularity in healthcare practices which results in disease-based diagnosis, intensive care, and therapy. Increasing global demand for genomics biomarkers for the better diagnosis and treatment of chronic diseases like cancer and cardiovascular diseases. Results in the growth in the demand for the genomics biomarker market in the forecast period.

Restraints:

Large-volume data storage

The genomics biomarker market has seen significant growth in the last decades. The market is primarily driven by the decreasing price of sequencing technologies and the rising government investment in the development of personalized medicines. These factors affect the market positively to the growth of the genomics biomarker market. All these factors create enormous amounts of data and issues regarding data storage are created. The larger amount of data can be the most challenging factor in the growth of the genomics biomarkers market in the predicted timeframe.

Opportunities:

Development of personalized medicine

The rising development of personalized medicine offers significant opportunities for the genomic biomarkers market. Genomic biomarkers play a crucial role in personalized medicine. The genomic biomarkers are capable of identifying specific genetic variations or patterns that can be used to identify the disease risk to select the required treatment pattern.

The rising adoption of personalized medicine and the growing understanding of the role of genomics in the healthcare sector promotes the continuation of research and development activities. Moreover, genomic biomarkers also help in monitoring the progress of treatment and predicting prognosis. Considering the multiple advantages offered by genomic biomarkers in the personalized medicine sector will act as a growth factor by offering multiple opportunities for the market’s growth.

Challenges:

Complicated web issues and lack of funding

Results from real-world analyses show that patients with a variety of tumor types are not being screened for recommendations suggested biomarkers, resulting in an inadequate utilization of targeted medicines. The "pervasive undertesting" of tumor-specific biomarkers and hereditary cancer risk has been bemoaned by researchers.  the researchers also have noted a complicated web of issues that are hindering the adoption of genomic testing, including knowledge gaps among healthcare professionals and assistance for interpreting test findings, flaws in tissue samples (especially in lung cancer), a lack of access to tests, and difficulties with funding.

Recent Development:

• In May 2023, Genomics England and UK MHRA announced that they have entered into the joint venture to launch the pioneering resources to understand to genetic makeup influences the safety of medicines.
• In May 2023, Kyoto University, Fujistsu, and Chordia Therapeutics announced that they have entered into a strategic collaboration to launch AI trial to discover biomarkers for new cancer drug. From these discoveries the collaboration’s vision to brand new cancer personalized treatments to individual patients.
• In Oct 2022, Biofidelity’s in North Carolina announced to launch its first commercial product, the company announced the $23 million and raising for keep up its ASPYRE-Lung diagnostic assay for lung cancer.

Major Key Players:

• Almac Group
• Cancer Genetics Inc
• Eurofins Scientific
• Thermo Fisher Scientific Inc
• Aepodia SA
• Epigenomics AG
• US Biomarkers Inc.
• Roche Diagnostics
• Myriad Genetics
• Bio-Rad Laboratories

Segments Covered in the Report

By Type 

• Predictive Biomarkers
• Prognostic Biomarkers

By Disease Indication

• Oncology
• Cardiovascular Diseases 
• Neurological Diseases
• Renal Disorders
• Others

By End-User 

• Hospitals
• Diagnostic Centers
• Others

Buy this Research Report@ https://www.precedenceresearch.com/checkout/2231

You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com | +1 9197 992 333